THE ASAHI SHIMBUN
July 22, 2020 at 14:21 JST
The health ministry’s building (Asahi Shimbun file photo)
The health ministry has approved the steroid drug dexamethasone for treating COVID-19 patients after it proved effective in a British clinical trial.
Dexamethasone, an anti-inflammatory medication, is the second added to the ministry's treatment guidebook for the novel coronavirus by July 21 following the antiviral drug remdesivir, which was approved in May.
In June, Oxford University in Britain announced that dexamethasone reduced the mortality rate of COVID-19 patients showing severe symptoms in a clinical trial.
Since dexamethasone is an approved drug for treating severe infectious diseases, including the new coronavirus, a new approval procedure is unnecessary, according to health officials.
With the health ministry's approval, more medical staff may utilize the steroid drug in their treatment of COVID-19 patients.
Currently, when drugs are used to treat patients with the new coronavirus, the medical treatment costs are covered by the government.
India drugmaker defends price of its COVID-19 favipiravir
July 21, 2020
Online health exam with drone delivering drugs a first in Japan
July 20, 2020
Gilead prices COVID-19 drug remdesivir at $2,340 per patient
June 30, 2020WHO moves to update COVID-19 guidance after ‘great news’ in drug study
June 17, 2020Fujifilm to double capacity of Danish drug facility
June 10, 2020
Stories about memories of cherry blossoms solicited from readers
Cooking experts, chefs and others involved in the field of food introduce their special recipes intertwined with their paths in life.
A series based on diplomatic documents declassified by Japan’s Foreign Ministry
A series on the death of a Japanese woman that sparked a debate about criminal justice policy in the United States
A series about Japanese-Americans and their memories of World War II
Here is a collection of first-hand accounts by “hibakusha” atomic bomb survivors.
